LEVOCARNITINE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for levocarnitine and what is the scope of freedom to operate?
Levocarnitine
is the generic ingredient in four branded drugs marketed by Leadiant Biosci Inc, Am Regent, Hikma, Teva Pharms Usa, Lyne, Novitium Pharma, Sciegen Pharms Inc, and Rising, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.There are four drug master file entries for levocarnitine. Seven suppliers are listed for this compound.
Summary for LEVOCARNITINE
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 8 |
| NDAs: | 12 |
| Drug Master File Entries: | 4 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 111 |
| Clinical Trials: | 24 |
| Patent Applications: | 6,920 |
| Drug Prices: | Drug price trends for LEVOCARNITINE |
| What excipients (inactive ingredients) are in LEVOCARNITINE? | LEVOCARNITINE excipients list |
| DailyMed Link: | LEVOCARNITINE at DailyMed |
Recent Clinical Trials for LEVOCARNITINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Children's Oncology Group | Phase 3 |
| University of California, Irvine | Early Phase 1 |
| Children's Hospital of Orange County | Early Phase 1 |
Pharmacology for LEVOCARNITINE
| Drug Class | Carnitine Analog |
Anatomical Therapeutic Chemical (ATC) Classes for LEVOCARNITINE
US Patents and Regulatory Information for LEVOCARNITINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novitium Pharma | LEVOCARNITINE | levocarnitine | TABLET;ORAL | 216384-001 | Dec 9, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novitium Pharma | LEVOCARNITINE | levocarnitine | SOLUTION;ORAL | 211676-001 | Aug 14, 2019 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sciegen Pharms Inc | LEVOCARNITINE | levocarnitine | SOLUTION;ORAL | 212533-001 | Nov 10, 2021 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Leadiant Biosci Inc | CARNITOR | levocarnitine | TABLET;ORAL | 018948-001 | Dec 27, 1985 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma | LEVOCARNITINE | levocarnitine | SOLUTION;ORAL | 077399-001 | Oct 25, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Am Regent | LEVOCARNITINE | levocarnitine | INJECTABLE;INJECTION | 075861-001 | Jun 22, 2001 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LEVOCARNITINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Leadiant Biosci Inc | CARNITOR | levocarnitine | INJECTABLE;INJECTION | 020182-001 | Dec 16, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Leadiant Biosci Inc | CARNITOR | levocarnitine | INJECTABLE;INJECTION | 020182-001 | Dec 16, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Leadiant Biosci Inc | CARNITOR | levocarnitine | INJECTABLE;INJECTION | 020182-001 | Dec 16, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
